Evonik showcases amino acids portfolio at China Feed Industry Expo 2024
- Spotlight on efficiency and sustainability benefits of amino acids portfolio
- Debut of the new Evonik joint venture that focuses on animal gut health & functional additive solutions
- In-booth demonstrations and insights on Evonik’s analytical services and methionine products
Essen, Germany. Evonik will highlight the supply security and sustainability benefits of its amino acids portfolio and present its latest products and solutions in animal nutrition at China Feed Industry Expo 2024. The company will also introduce its new joint venture Evonik Vland Biotech, which focuses on animal gut health and functional additive solutions, for the first time at an industrial fair in China.
“Evonik has been present in China’s animal nutrition industry for more than 20 years, and the country continues to be a very important growth market. We're committed to providing feed additives and system solutions that are both competitive and of the highest quality to meet the feed challenges of today and tomorrow,” said Madeline Tan, regional head of Animal Nutrition at Evonik for Asia Pacific.
Visitors to the Evonik booth can learn more about the company’s portfolio of amino acids, including MetAMINO® for monogastric animals and Mepron® for ruminants, as well as the bioefficacy concept recently reaffirmed in the second edition of the MetAMINO® ATLAS. In addition, the Evonik team will provide details on the current upgrade of its methionine production hub in Singapore, including the sustainability and supply security benefits once completed. Visitors to the booth will also be able to see a hands-on demonstration of the AMINONIR® analytical service.
Evonik’s PROXYMet™ product, a mixture of 65% DL-methionine and 35% calcium carbonate, is designed to easily demonstrate the relative bioefficacy of 65% because it can replace methionine hydroxy analog products at a 1:1 ratio on a product-to-product basis. Visitors can see PROXYMet™ for themselves in a sample exhibition of the product at the booth.
As another highlight of Evonik’s presence at this year’s China Feed Industry Expo, Evonik Vland Biotech, the newly formed joint venture between Evonik China and Shandong Vland Biotech, will make its debut at a trade show. The joint venture with Vland strengthens the biosolutions portfolio of Evonik's Nutrition & Care division with innovative products such as probiotics for animal gut health.
The joint venture’s product range features probiotics such as GutCare® and GutPlus®, along with GuanAMINO® for improved energy metabolism in livestock production. Additionally, Evonik Vland Biotech will introduce two pioneering products: SpeoCare™ T60, designed to enhance intestinal immunity, and GutPlus® Virsorb, aimed at alleviating rotavirus infections.
“We are excited to present our entire animal gut health portfolio and commitment to the local market for the first time,” said Dr. Xu Wang, General Manager of Evonik Vland Biotech.
China Feed Industry Expo 2024 takes place between April 18-20 at the Xiamen International Convention and Exhibition Center. The Evonik booth is located in Hall C4, Booth C4A108.
Company information
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15.3 billion and an operating profit (adjusted EBITDA) of €1.66 billion in 2023. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. More than 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.
About Nutrition & Care
The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.61 billion in 2023 with more than 5,600 employees.
Disclaimer
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.